Drug Delivery Platforms
•230 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (230)
| Company | Market Cap | Price |
|---|---|---|
|
TLSI
TriSalus Life Sciences, Inc.
Core PEDD drug-delivery platform technology powering TriNav systems.
|
$370.02M |
$7.32
+0.48%
|
|
BNTC
Benitec Biopharma Inc.
The Silence and Replace platform includes a drug delivery vector approach, fitting Drug Delivery Platforms.
|
$369.44M |
$10.90
-0.09%
|
|
NGNE
Neurogene Inc.
EXACT is a proprietary platform technology for drug delivery/regulation of transgene expression in gene therapy.
|
$341.24M |
$23.65
-1.09%
|
|
DCTH
Delcath Systems, Inc.
Delcath's core offering is a Drug Delivery Platform enabling hepatic delivery of chemotherapy (PHx/HEPZATO KIT) for liver-directed treatment.
|
$325.95M |
$9.23
+0.05%
|
|
ALDX
Aldeyra Therapeutics, Inc.
RASP modulation platform described as a drug-delivery/platform technology.
|
$312.55M |
$4.99
-4.04%
|
|
SCPH
scPharmaceuticals Inc.
Drug Delivery Platforms is a core technology enabling the subcutaneous administration of FUROSCIX.
|
$299.33M |
$5.67
|
|
EPRX
Eupraxia Pharmaceuticals Inc.
Diffusphere is Eupraxia's proprietary drug-delivery platform enabling localized, extended-release formulation, a core product/technology they directly develop and apply to its pipeline candidates EP-104IAR and EP-104GI.
|
$294.15M |
$8.17
-0.12%
|
|
CADL
Candel Therapeutics, Inc.
enLIGHTEN HSV-based platform represents a drug delivery platform used to design and optimize viral immunotherapies.
|
$290.94M |
$5.39
+1.70%
|
|
SLN
Silence Therapeutics plc
Platform-based drug delivery (GalNAc-siRNA) enabling targeted delivery for siRNA therapies.
|
$272.74M |
$5.19
-10.21%
|
|
RNA
Avidity Biosciences, Inc.
Drug Delivery Platforms: AOC platform is a delivery technology for targeting oligonucleotides to specific tissues.
|
$256.62M |
$16.39
-0.88%
|
|
CLPT
ClearPoint Neuro, Inc.
SmartFlow cannula represents a drug-delivery platform for targeted brain infusion, tied to cell/gene therapy delivery approaches.
|
$254.14M |
$8.91
-0.34%
|
|
SLGL
Sol-Gel Technologies Ltd.
Proprietary microencapsulation drug-delivery platform is a core technology Sol-Gel uses to formulate topical therapies.
|
$246.26M |
$89.64
+1.40%
|
|
TARA
Protara Therapeutics, Inc.
IV Choline Chloride is described as a platform for phospholipid substrate replacement, i.e., a Drug Delivery Platform.
|
$239.21M |
$6.03
-2.74%
|
|
OBIO
Orchestra BioMed Holdings, Inc.
Virtue SAB represents a drug-delivery platform delivering extended-release sirolimus to the vessel wall.
|
$236.32M |
$4.38
+1.04%
|
|
ALEC
Alector, Inc.
Alector Brain Carrier (ABC) is a proprietary drug delivery platform to enhance brain exposure and enable subcutaneous administration.
|
$234.68M |
$2.08
-3.26%
|
|
VYGR
Voyager Therapeutics, Inc.
ALPL-based non-viral shuttle and TRACER capsids represent a Drug Delivery Platforms technology.
|
$229.09M |
$3.92
-4.96%
|
|
QNCX
Quince Therapeutics, Inc.
Quince's AIDE platform is a drug-delivery platform encapsulating drugs in autologous red blood cells.
|
$226.67M |
$4.28
-2.73%
|
|
CPMV
Mosaic ImmunoEngineering Inc.
Drug delivery platforms tag fits the proprietary plant virus nanoparticle delivery technology used to modulate immune responses.
|
$222.38M |
$0.70
|
|
PEPG
PepGen Inc.
The Enhanced Delivery Oligonucleotide (EDO) platform represents a drug delivery technology, justifying the Drug Delivery Platforms tag.
|
$221.73M |
$6.75
+5.14%
|
|
HRTX
Heron Therapeutics, Inc.
Biochronomer drug-delivery technology is a platform enabling extended-release formulations across Heron's products.
|
$207.20M |
$1.07
-4.87%
|
|
TLSA
Tiziana Life Sciences Ltd
TLSA utilizes an intranasal delivery method for Foralumab, representing a Drug Delivery Platforms approach.
|
$185.78M |
$1.45
+1.05%
|
|
MOLN
Molecular Partners AG
DARPin platform represents a drug-delivery/modular platform enabling targeted biologics.
|
$184.52M |
N/A
|
|
NTHI
Neonc Technologies Holdings, Inc.
Proprietary drug delivery platform enabling brain tumor targeting and BBB bypass; platform used for delivery of therapeutics.
|
$184.50M |
$9.68
+0.52%
|
|
STRO
Sutro Biopharma, Inc.
XpressCF+/ADC platform constitutes a drug delivery platform used to create and optimize ADCs.
|
$180.65M |
$21.04
-1.27%
|
|
EDIT
Editas Medicine, Inc.
Drug Delivery Platforms: proprietary delivery platform (tLNP) enabling in vivo gene editing.
|
$178.94M |
$2.04
+2.76%
|
|
MIST
Milestone Pharmaceuticals Inc.
Milestone's nasal spray represents a drug delivery platform/format for self-administration.
|
$174.24M |
$2.23
+9.02%
|
|
ARCT
Arcturus Therapeutics Holdings Inc.
Core technology platforms STARR sa-mRNA and LUNAR delivery system enabling RNA therapeutics.
|
$169.72M |
$6.21
+1.22%
|
|
VXRT
Vaxart, Inc.
The VAAST platform constitutes a Drug Delivery Platform enabling oral, needle-free vaccines with mucosal immunity and room-temperature stability.
|
$166.40M |
$0.59
|
|
THTX
Theratechnologies Inc.
SORT1+ Technology platform functions as a drug-delivery platform enabling peptide-drug conjugates.
|
$155.87M |
$3.39
|
|
RLMD
Relmada Therapeutics, Inc.
NDV-01 employs a sustained-release drug-delivery platform for intravesical administration.
|
$155.00M |
$4.67
-3.51%
|
|
IKT
Inhibikase Therapeutics, Inc.
Prodrug technology used in IKT-001Pro represents a drug-delivery platform approach.
|
$145.31M |
$1.92
-1.79%
|
|
MRSN
Mersana Therapeutics, Inc.
Dolasynthen and Immunosynthen platforms are drug delivery platforms enabling targeted ADC payload delivery.
|
$145.13M |
$29.10
+0.07%
|
|
ELTX
Elicio Therapeutics, Inc.
AMP platform described as a drug delivery platform targeting lymph nodes.
|
$144.76M |
$8.74
-1.35%
|
|
ADAG
Adagene Inc.
Drug Delivery Platforms capturing the platform-based approach to activating antibodies in tumors.
|
$138.03M |
$3.06
+4.44%
|
|
ORMP
Oramed Pharmaceuticals Inc.
Oramed's POD platform constitutes the core drug-delivery technology enabling oral administration of therapeutic proteins (e.g., oral insulin).
|
$134.08M |
$3.37
+3.06%
|
|
ARTV
Artiva Biotherapeutics, Inc.
AlloNK represents a drug-delivery platform concept (off-the-shelf cell therapy) enabling administration of therapy.
|
$133.36M |
$5.50
+0.64%
|
|
GOSS
Gossamer Bio, Inc.
Inhaled seralutinib represents a drug-delivery platform that concentrates therapy in the lungs to treat pulmonary hypertension, a major differentiator.
|
$131.88M |
$0.53
-8.43%
|
|
SGMO
Sangamo Therapeutics, Inc.
STAC-BBB represents a CNS drug-delivery platform enabling systemic delivery across the blood-brain barrier.
|
$119.24M |
$0.39
-0.56%
|
|
ALXO
ALX Oncology Holdings Inc.
ALX2004 leverages a proprietary linker-payload platform, aligning with the Drug Delivery Platforms category.
|
$117.28M |
$2.19
+0.23%
|
|
ACOG
Alpha Cognition Inc. Common Stock
The company references sublingual and coated tablet formulations, indicating a drug delivery platform focus.
|
$105.05M |
$6.50
+5.18%
|
|
GNLX
Genelux Corporation
CHOICE is a platform-based drug delivery approach for immunotherapies, fitting Drug Delivery Platforms.
|
$101.23M |
$2.69
+0.37%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RaniPill is the core drug-delivery platform enabling oral administration of biologics, central to the company's offering.
|
$97.74M |
$1.35
-0.74%
|
|
PYXS
Pyxis Oncology, Inc.
MICVO employs a drug-delivery platform approach (extracellular matrix targeting with a cleavable linker and cytotoxic payload).
|
$92.41M |
$1.42
-4.70%
|
|
ADVM
Adverum Biotechnologies, Inc.
The program relies on a proprietary drug delivery platform (vector-based) for sustained expression of a therapeutic protein.
|
$91.49M |
$4.38
+0.34%
|
|
INO
Inovio Pharmaceuticals, Inc.
CELLECTRA delivery technology represents a drug delivery platform enabling in vivo DNA plasmid delivery.
|
$84.50M |
$1.57
-0.94%
|
|
BMEA
Biomea Fusion, Inc.
Platform technology (FUSION System) used to discover/develop covalent small molecule drugs, representing a drug discovery platform.
|
$82.72M |
$1.39
|
|
MCRB
Seres Therapeutics, Inc.
MbTx Platform is Seres' core drug-delivery platform enabling the design and cultivation of targeted live biotherapeutic consortia.
|
$79.93M |
$9.21
+0.88%
|
|
ASRT
Assertio Holdings, Inc.
Sympazan's PharmFilm technology and related drug-delivery approaches indicate a Drug Delivery Platforms capability.
|
$77.44M |
$12.18
+0.91%
|
|
VANI
Vivani Medical, Inc.
Vivani's NanoPortal is a proprietary drug-implant platform enabling ultra long-acting, localized drug delivery.
|
$74.65M |
$1.30
+3.17%
|
|
CLNN
Clene Inc.
Clene's proprietary clean-surfaced nanotechnology platform operates as a drug delivery platform for CNM-Au8.
|
$72.13M |
$7.22
|
|
PYPD
PolyPid Ltd.
D-PLEX100 leverages PolyPid's PLEX drug-delivery platform to provide localized, prolonged antibiotic release at the surgical site.
|
$66.53M |
$4.25
+0.12%
|
|
IBIO
iBio, Inc.
ShieldTx and related antibody engineering imply a Drug Delivery Platform approach to spatially control activity.
|
$63.64M |
$2.75
-2.83%
|
|
ATHE
Alterity Therapeutics Limited
Alterity's iron chaperone platform represents a drug-delivery/platform technology that redistributes iron to modulate disease pathways.
|
$62.07M |
$3.71
+9.12%
|
|
GRCE
Grace Therapeutics, Inc.
The company emphasizes proprietary drug-delivery platforms to reformulate existing compounds, a clear fit for 'Drug Delivery Platforms'.
|
$60.61M |
$4.29
+4.13%
|
|
ENTX
Entera Bio Ltd.
Entera Bio's N-Tab platform is a drug-delivery platform enabling oral administration of large-molecule peptides.
|
$59.36M |
$1.33
+2.31%
|
|
NTRB
Nutriband Inc.
Direct AVERSA drug-delivery platform enabling abuse-deterrent transdermal patches (lead product AVERSA Fentanyl) and related patch technologies.
|
$50.55M |
$4.22
+0.48%
|
|
VRCA
Verrica Pharmaceuticals Inc.
YCANTH uses a proprietary drug-device combination applicator, aligning with a drug delivery platform.
|
$50.35M |
$5.12
-3.94%
|
|
OSTX
OS Therapies Incorporated
Drug Delivery Platforms tag captures the tunable linker/ delivery platform used in OST-tADC.
|
$46.88M |
$1.48
+0.34%
|
|
LPCN
Lipocine Inc.
Lipocine leverages the proprietary Lipral drug delivery platform, a core asset that enables oral delivery of challenging molecules and underpins its product candidates.
|
$45.68M |
$8.46
+0.42%
|
|
LSTA
Lisata Therapeutics, Inc.
Certepetide functions as a drug-delivery platform to enhance tumor penetration and co-administered therapies.
|
$39.23M |
$4.41
-1.67%
|
|
ATNM
Actinium Pharmaceuticals, Inc.
ARC/Radiopharmaceutical platform represents a drug delivery platform enabling targeted radiotherapy.
|
$38.37M |
$1.19
-3.25%
|
|
XLO
Xilio Therapeutics, Inc.
Drug Delivery Platforms reflects Xilio's tumor-activation masking technology designed to localize activity within tumors.
|
$37.95M |
$0.73
+0.33%
|
|
TVGN
Tevogen Bio Holdings Inc.
ExacTcell and TVGN platform described as a drug delivery platform enabling cell therapies.
|
$36.63M |
$0.19
|
|
GBIO
Generation Bio Co.
ctLNP is a proprietary drug delivery platform enabling targeted, redosable delivery of nucleic acids.
|
$35.97M |
$5.36
+0.37%
|
|
MURA
Mural Oncology plc
Engineered cytokine platform underlying the programs represents a Drug Delivery Platform/therapeutic delivery approach.
|
$35.34M |
$2.03
-0.49%
|
|
NXTC
NextCure, Inc.
NextCure’s ADC technology represents a drug delivery platform that enables targeted payload delivery to tumors.
|
$33.72M |
$12.46
-1.11%
|
|
NMTC
NeuroOne Medical Technologies Corporation
sEEG-based drug delivery system platform enabling localized therapeutic delivery from neural implants.
|
$33.63M |
$0.67
+0.19%
|
|
MDCX
Medicus Pharma Ltd. Common Stock
Directly markets/provides a proprietary drug-delivery platform (D-MNA) enabling localized chemotherapy delivery.
|
$30.17M |
$0.88
-36.23%
|
|
ELUT
Elutia Inc.
EluPro embodies a Drug Delivery Platform delivering antibiotics from the biomatrix at the implant site.
|
$29.59M |
$0.70
-0.37%
|
|
BTAI
BioXcel Therapeutics, Inc.
Sublingual film formulation BXCL501 represents a drug-delivery platform; included as Drug Delivery Platforms.
|
$29.26M |
$2.04
-1.69%
|
|
HOWL
Werewolf Therapeutics, Inc.
PREDATOR platform represents a drug delivery platform enabling tumor-selective activation.
|
$28.01M |
$0.61
-0.13%
|
|
PASG
Passage Bio, Inc.
PBFT02 leverages a drug delivery platform (AAV1/ICM) to deliver progranulin to the CNS.
|
$26.83M |
$8.24
-2.37%
|
|
RNTX
Rein Therapeutics Inc.
LTI-3.00 employs a dry powder inhalation delivery approach, representing a Drug Delivery Platforms category.
|
$26.57M |
$1.16
-3.33%
|
|
AYTU
Aytu BioPharma, Inc.
The company employs a Time Release Resin Particle (TRRP) proprietary technology, aligning with the 'Drug Delivery Platforms' category.
|
$26.54M |
$2.63
+0.96%
|
|
CUE
Cue Biopharma, Inc.
Immuno-STAT represents a drug delivery platform for targeted, injectable biologics.
|
$25.93M |
$0.33
+9.43%
|
|
THAR
Tharimmune, Inc.
TH023 leverages external oral-delivery platforms (Soteria/Phloral) via Intract, representing a Drug Delivery Platform technology.
|
$23.83M |
$4.74
-5.58%
|
|
VTGN
VistaGen Therapeutics, Inc.
Pherine platform represents a non-systemic intranasal drug-delivery approach developed by the company.
|
$23.39M |
$0.56
-5.34%
|
|
DARE
Daré Bioscience, Inc.
Drug Delivery Platforms: Daré's core IDDS platform is used to deliver hormones and contraceptive agents (e.g., DARE-LARC1) and supports multiple pipeline programs, making this a primary product/technology category.
|
$22.92M |
$1.69
+0.90%
|
|
AKTX
Akari Therapeutics, Plc
Drug delivery platforms conceptually underpin the novel ADC payloads and linker technologies.
|
$20.35M |
$0.28
-31.68%
|
|
TLPH
Talphera, Inc.
The company emphasizes drug delivery platform concepts through lyophilized nafamostat formulations and IV/compounded administration approaches.
|
$18.71M |
$0.91
-2.03%
|
|
OTLC
Oncotelic Therapeutics, Inc.
Nanoparticle-based delivery platform for six anticancer agents constitutes a Drug Delivery Platform.
|
$17.30M |
$0.05
|
|
SER
Serina Therapeutics, Inc.
Direct proprietary POZ drug delivery platform enabling long-acting, subcutaneous drug release for CNS therapeutics.
|
$17.12M |
$1.66
-0.60%
|
|
EVOK
Evoke Pharma, Inc.
Gimoti relies on a nasal drug-delivery platform/technology, making Drug Delivery Platforms a core investable theme for Evoke's product strategy.
|
$17.07M |
$10.98
+0.32%
|
|
GNTA
Genenta Science S.p.A.
Temferon uses a drug-delivery platform to express payloads in the tumor microenvironment.
|
$16.65M |
$0.95
+4.49%
|
|
PALI
Palisade Bio, Inc.
PALI-2108 employs a gut-restricted prodrug delivery approach, representing a Drug Delivery Platforms technology.
|
$15.87M |
$1.74
-0.29%
|
|
JUNS
Jupiter Neurosciences, Inc.
Drug Delivery Platforms: JOTROL is a proprietary micellar delivery system improving bioavailability.
|
$15.78M |
$0.44
-2.27%
|
|
LEXX
Lexaria Bioscience Corp.
Lexaria's DehydraTECH is a proprietary drug delivery platform that enhances API absorption and enables oral formulations.
|
$15.76M |
$0.70
-1.27%
|
|
APLT
Applied Therapeutics, Inc.
ARI platform represents a drug-delivery/targeting platform aiming for tissue-specific penetration, a defined drug-delivery platform category.
|
$14.83M |
$0.11
+4.37%
|
|
INTS
Intensity Therapeutics, Inc.
DfuseRx platform and INT230-6.00 involve a drug-delivery platform enabling intratumoral delivery and systemic immune effects.
|
$14.49M |
$7.63
-0.84%
|
|
PVCT
Provectus Biopharmaceuticals, Inc.
Veripure represents a drug-delivery platform for pharmaceutical-grade RBS and PV-10 formulations.
|
$13.60M |
$0.06
|
|
HOTH
Hoth Therapeutics, Inc.
BioLexa platform and HT-001 formulation imply a drug delivery platform approach (localized/topical delivery).
|
$13.39M |
$1.00
-3.37%
|
|
LIPO
Lipella Pharmaceuticals Inc.
Lipella's core metastable liposome drug delivery platform enables targeted, localized mucosal drug formulations.
|
$12.20M |
$0.31
|
|
SYBX
Synlogic, Inc.
Synlogic positions its Synthetic Biotics as a Drug Delivery Platform enabling localized GI therapy.
|
$12.17M |
$1.05
+0.96%
|
|
COSM
Cosmos Health Inc.
Uses nanoemulsification technology to enhance absorption (e.g., Melatonin Spray), representing a Drug Delivery Platforms capability.
|
$11.68M |
$0.39
+1.14%
|
|
BCAB
BioAtla, Inc.
CAB platform is a conditional antibody/drug delivery platform used to activate drug in tumor microenvironment.
|
$9.65M |
$0.17
+4.02%
|
|
CLRB
Cellectar Biosciences, Inc.
PDC platform represents a drug delivery platform enabling intracellular payload delivery to tumor cells.
|
$9.54M |
$2.73
-8.70%
|
|
NXGL
NEXGEL, Inc.
NXGEL's hydrogel platform enables drug delivery and controlled release applications.
|
$9.28M |
$1.21
+0.42%
|
|
IMNN
Imunon, Inc.
TheraPlas is a drug delivery platform enabling loco-regional cytokine production.
|
$9.10M |
$4.16
+0.73%
|
|
QNRX
Quoin Pharmaceuticals, Ltd.
Invisicare-based drug-delivery platform is used for QRX003 and other topical formulations, constituting a major product/technology platform.
|
$8.75M |
$8.72
+2.59%
|
|
BOLT
Bolt Biotherapeutics, Inc.
Bolt's Boltbody ISAC platform is a drug-delivery platform designed to deliver immune-stimulating payloads via antibodies.
|
$8.68M |
$4.64
+0.32%
|
Showing page 2 of 3 (230 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
